Navidea Biopharmaceuticals Announces Underwritten Sale of Common Stock

Published: Apr 24, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that it has priced an underwritten sale of common stock in a transaction involving J.P. Morgan Asset Management and one other institutional investor. Both of these investors also participated in a similar transaction in early February. In the offering, 2,100,000 shares were sold in an at-market transaction for a price of $2.43 per share for gross proceeds of approximately $5.1 million. The net proceeds of the financing will be used to fund Navidea’s ongoing operations. The sale is expected to close on or about April 29, 2013, subject to the satisfaction of customary closing conditions.

Help employers find you! Check out all the jobs and post your resume.

Back to news